Click the title above for a link to open the Pharmaceutical Commerce February 2025 issue in an interactive PDF format.

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain. Third-party ...

Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4. Amid last week’s 30-day pause that had been placed on Canada ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific ...

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s ...

In recent years, the landscape of retail pharmacy has changed significantly due to massive financial, legislative, and social pressures, creating a challenging environment for both large and small ...

2024 was a pivotal year for the patient support landscape, as the space underwent a substantial shift shaped by market dynamics, regulatory changes, and the evolving needs of patients. After a quarter ...

The pharmaceutical industry has witnessed a resurgence of mergers and acquisitions (M&As) as companies seek to gain a competitive edge, accelerate innovation, and drive growth. By consolidating ...

Illicit trade activity (ITA) in the pharmaceutical industry has been on a steady rise globally since the Pharmaceutical Security Institute (PSI) began reporting annual incident statistics more than 22 ...

A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency. After the start of the COVID-19 pandemic in 2020, ...

Welcome to the second installment of the “Popping the Gross-to-Net Bubble” series. In this column, I’ll dive into actionable steps pharmaceutical manufacturers can take to address this issue. This ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, describes what the approach of pharma ...